[Disaccharidases of the small-intestinal mucosa of the rat under therapy with ifosfamide (author's transl)].
In rats, treatment with 3-(2-chloroethyl)-2-(2-chloroethyl-amino)-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide (ifosfamide; Asta Z 4942) results in a decrease of intestinal disaccharidase activities concomitant with morphological alterations of the mucosa. Even after morphological restoration of the tissue, enzyme activities remain reduced for a couple of days. Examinations of patients treated with ifosfamide will show whether there are comparable effects also in man which may lead to malabsorption of disaccharidases.
D000818:Animals; D003520:Cyclophosphamide / Q000031:analogs & derivatives*; D004186:Disaccharidases / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005696:Galactosidases / Q000378:metabolism; D005959:Glucosidases / Q000378:metabolism; D007069:Ifosfamide / Q000494:pharmacology* / Q000633:toxicity; D007413:Intestinal Mucosa / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D007421:Intestine, Small / Q000201:enzymology; D007422:Intestines / Q000473:pathology; D008297:Male; D051381:Rats; D013393:Sucrase / Q000378:metabolism
D003520:Cyclophosphamide; D004186:Disaccharidases; D005696:Galactosidases; D005959:Glucosidases; D013393:Sucrase; D007069:Ifosfamide
Disaccharidasen der Dünndarmschleimhaut der Ratte unter der Behandlung mit Ifosfamid